ScienceMarch 3, 2026
Eledon Pharmaceuticals (ELDN): CD40L Pathway, Tegoprubart, Transplant & ALS Pipeline — February 2026
Eledon Pharmaceuticals (Nasdaq: ELDN) is a clinical-stage biotech targeting the CD40L pathway with tegoprubart, an IgG1 anti-CD40L antibody. Phase 2 BESTOW kidn
By ObjectWire Editorial